Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 3 double-blind multicenter study of baricitinib in systemic lupus erythematosus
MOH_2020-07-19_009148Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (2 arms), sponsored by Eli Lilly and Company. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2020-07-19_009148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-19_009148.